Top Suppliers:I want be here
  • DC Chemicals Limited
  • China
  • Product Name: OE312
  • Price: $Inquiry/100mg $Inquiry/250mg $Inquiry/500mg
  • Purity: 98.0%
  • Stocking Period: 3 Day
  • Contact: Tony Cao
Related CAS#:
1188-38-1 2450-11-5
2432-85-1 2432-81-7
2432-46-4 11043-91-7
105603-54-1 243869-48-9
105622-98-8 14047-56-4

1188-38-1

1188-38-1 structure
1188-38-1 structure
  • Name: Carglumic Acid
  • Chemical Name: carglumic acid
  • CAS Number: 1188-38-1
  • Molecular Formula: C6H10N2O5
  • Molecular Weight: 190.15400
  • Catalog: Biochemical Amino acids and their derivatives Glutamic acid derivative
  • Create Date: 2018-06-13 14:23:15
  • Modify Date: 2024-01-06 17:56:53
  • Carglumic acid, a functional analogue of N-acetylglutamate (NAG) and a carbamoyl phosphate synthetase 1 (CPS1) activator, is used to treat acute and chronic hyperammonemia associated with NAG synthase (NAGS) deficiency.
Name carglumic acid
Synonyms (S)-2-Ureidopentanedioic acid
(2S)-2-(carbamoylamino)pentanedioic acid
N-Carbamyl-L-glutamic Acid
MFCD00047874
Description Carglumic acid, a functional analogue of N-acetylglutamate (NAG) and a carbamoyl phosphate synthetase 1 (CPS1) activator, is used to treat acute and chronic hyperammonemia associated with NAG synthase (NAGS) deficiency.
Related Catalog
Target

CPS1[1]
In Vitro Carglumic acid suppresses cell viability in the pancreatic ductal adenocarcinoma cell lines, triple-negative breast cancer cell lines, hepatoma cell lines, and human non-small cell lung carcinoma cell lines in a dose-dependent manner. The 50% inhibitory concentration (IC50) of Carglumic acid against those cell lines is between 5 and 7.5 mM. The results show that Carglumic acid does not induce complete cell cycle arrest. Instead, there are more sub-G1 cells among Carglumic acid-treated AsPC1 and MDA-MB-231 cells than among untreated cells. In AsPC1 and HPDE-E6E7 cells, the IC50s of Carglumic acid are 5 mM and over 10 mM, respectively . In MDA-MB-231 and MCF-12A cells, the IC50s of Carglumic acid are 5 mM and 6 mM, respectively[1].
In Vivo The results show that Carglumic acid, but not the vehicle control, markedly inhibits tumor growth. In the orthotopic pancreatic cancer model, tumor growth inhibition by Carglumic acid on day 21 is 80% (P<0.01). In the orthotopic triple-negative breast cancer model, tumor growth inhibition by Carglumic acid on day 20 is 82% (P<0.01). These results indicate that Carglumic acid suppresses tumor growth in pancreatic cancer and triple-negative breast cancer. On day 20, mean tumor growth inhibition in orally and intravenously treated mice is 55% and 93%, respectively, relative to untreated mice (P<0.01)[1].
Kinase Assay Caspase activity is measured by using a fluorimetric caspase-3 assay kit. In brief, cells that are treated with Carglumic Acid or that are left untreated are lysed in a lysis buffer, and 50 μg of protein lysate is incubated with Ac-DEVD-AMC substrate in the assay buffer for 1 h. The resultant fluorescence signals are read by using a fluorometer (excitation 360 nm, emission 460 nm), and the results are tabulated as fold changes relative to the untreated control cells[1].
Cell Assay Cell viability is evaluated by MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide) assay. In brief, various cancer cell lines are seeded (1×104 cells/well) in a 96-well plate and treated with different doses of Carglumic Acid. After 48 h, 50 μL of MTT solution per well (stock solution concentration 5 mg/mL) is added to each well, and the cells are incubated for 2 h more, followed by addition of 100 μL of dimethyl sulfoxide to each well. Absorbance at 570 nm is measured immediately using a multiwell scanner[1].
Animal Admin For orthotopic cancer models, AsPC1/luc human pancreatic cancer cells (1×106) are injected into the pancreas of nude mice or MDA-MB-231 human triple-negative breast cancer cells (3×106) are injected into the mammary fat pad of nude mice. Carglumic acid is administered to mice 5 days after tumor inoculation in the pancreatic cancer model and 7 days after tumor inoculation in the triple-negative breast cancer model. Tumor-bearing mice receive a Carglumic acid dose of 120 mg/kg orally every day for 10 days, 60 mg/kg orally three times per week for 2 weeks, or 60 mg/kg intravenously three times per week for 2 weeks. Tumor volume is determined by measuring luciferase signals using the in vivo imaging system in the pancreatic cancer model[1].
References

[1]. Chen CT, et al. Carglumic acid promotes apoptosis and suppresses cancer cell proliferation in vitro and in vivo. Am J Cancer Res. 2015 Nov 15;5(12):3560-9.
Density 1.499g/cm3
Boiling Point 438.1ºC at 760 mmHg
Melting Point 174°
Molecular Formula C6H10N2O5
Molecular Weight 190.15400
Flash Point 218.8ºC
Exact Mass 190.05900
PSA 129.72000
LogP 0.06390
Vapour Pressure 6.7E-09mmHg at 25°C
Index of Refraction 1.544
Storage condition 2-8°C

CHEMICAL IDENTIFICATION

RTECS NUMBER :
LZ9870000
CHEMICAL NAME :
L-Glutamic acid, N-(aminocarbonyl)-
CAS REGISTRY NUMBER :
1188-38-1
LAST UPDATED :
199209
DATA ITEMS CITED :
1
MOLECULAR FORMULA :
C6-H10-N2-O5
MOLECULAR WEIGHT :
190.18

HEALTH HAZARD DATA

ACUTE TOXICITY DATA

TYPE OF TEST :
LD50 - Lethal dose, 50 percent kill
ROUTE OF EXPOSURE :
Oral
SPECIES OBSERVED :
Rodent - mouse
DOSE/DURATION :
>1 gm/kg
TOXIC EFFECTS :
Details of toxic effects not reported other than lethal dose value
REFERENCE :
KHFZAN Khimiko-Farmatsevticheskii Zhurnal. Chemical Pharmaceutical Journal. For English translation, see PCJOAU. (V/O Mezhdunarodnaya Kniga, 113095 Moscow, USSR) V.1- 1967- Volume(issue)/page/year: 24(4),32,1990
Symbol GHS07
GHS07
Signal Word Warning
Hazard Statements H302-H315-H319-H335
Precautionary Statements P261-P305 + P351 + P338
Personal Protective Equipment dust mask type N95 (US);Eyeshields;Gloves
Hazard Codes Xi: Irritant;
Risk Phrases R36/37/38
Safety Phrases 26-36/37
RIDADR NONH for all modes of transport
WGK Germany 3
RTECS LZ9870000
56-86-0 structure

56-86-0
57-13-6 structure

57-13-6

~64%

1188-38-1 structure

1188-38-1
Literature: Verardo, Giancarlo; Geatti, Paola; Strazzolini, Paolo Synthetic Communications, 2007 , vol. 37, # 11 p. 1833 - 1844
590-28-3 structure

590-28-3
56-86-0 structure

56-86-0

~%

1188-38-1 structure

1188-38-1
Literature: Pharmaceutical Chemistry Journal, , vol. 12, # 5 p. 601 - 606 Khimiko-Farmatsevticheskii Zhurnal, , vol. 12, # 5 p. 53 - 59

Chemsrc provides CAS#:1188-38-1 MSDS, density, melting point, boiling point, structure, formula, molecular weight, synthetic route, etc.
title: CAS No. 1188-38-1 | Chemsrc address: https://www.chemsrc.com/en/baike/1085871.html

Home | MSDS/SDS Database Search | Journals | Product Classification | Biologically Active Compounds | Selling Leads | About Us | Disclaimer

Copyright © 2024 ChemSrc All Rights Reserved